357 related articles for article (PubMed ID: 21566011)
1. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH
Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011
[TBL] [Abstract][Full Text] [Related]
2. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.
Vlaming ML; van Esch A; Pala Z; Wagenaar E; van de Wetering K; van Tellingen O; Schinkel AH
Mol Cancer Ther; 2009 Dec; 8(12):3350-9. PubMed ID: 19996279
[TBL] [Abstract][Full Text] [Related]
3. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
Vlaming ML; Pala Z; van Esch A; Wagenaar E; de Waart DR; van de Wetering K; van der Kruijssen CM; Oude Elferink RP; van Tellingen O; Schinkel AH
Clin Cancer Res; 2009 May; 15(9):3084-93. PubMed ID: 19383815
[TBL] [Abstract][Full Text] [Related]
4. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.
Vlaming ML; Pala Z; van Esch A; Wagenaar E; van Tellingen O; de Waart DR; Oude Elferink RP; van de Wetering K; Schinkel AH
Clin Cancer Res; 2008 Dec; 14(24):8152-60. PubMed ID: 19088030
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.
Wang Z; Zhou Q; Kruh GD; Gallo JM
Drug Metab Dispos; 2011 Nov; 39(11):2155-61. PubMed ID: 21841039
[TBL] [Abstract][Full Text] [Related]
6. Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2.
de Waart DR; Vlaming ML; Kunne C; Schinkel AH; Oude Elferink RP
Drug Metab Dispos; 2009 Aug; 37(8):1698-702. PubMed ID: 19443695
[TBL] [Abstract][Full Text] [Related]
7. The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.
Sane R; Wu SP; Zhang R; Gallo JM
Drug Metab Dispos; 2014 Apr; 42(4):537-40. PubMed ID: 24464805
[TBL] [Abstract][Full Text] [Related]
8. Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice.
Nezasa K; Tian X; Zamek-Gliszczynski MJ; Patel NJ; Raub TJ; Brouwer KL
Drug Metab Dispos; 2006 Apr; 34(4):718-23. PubMed ID: 16434545
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
Bruhn O; Cascorbi I
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
11. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.
Hegyi M; Arany A; Semsei AF; Csordas K; Eipel O; Gezsi A; Kutszegi N; Csoka M; Muller J; Erdelyi DJ; Antal P; Szalai C; Kovacs GT
Oncotarget; 2017 Feb; 8(6):9388-9398. PubMed ID: 27566582
[TBL] [Abstract][Full Text] [Related]
13. Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3).
Kitamura Y; Hirouchi M; Kusuhara H; Schuetz JD; Sugiyama Y
J Pharmacol Exp Ther; 2008 Nov; 327(2):465-73. PubMed ID: 18719291
[TBL] [Abstract][Full Text] [Related]
14. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide Increases Hepatic Exposure to Methotrexate and Its Metabolite by Differentially Regulating Multidrug Resistance-Associated Protein Mrp2/3/4 Transporters via Peroxisome Proliferator-Activated Receptor
Wang L; Ma L; Lin Y; Liu X; Xiao L; Zhang Y; Xu Y; Zhou H; Pan G
Mol Pharmacol; 2018 Jun; 93(6):563-574. PubMed ID: 29618584
[TBL] [Abstract][Full Text] [Related]
16. Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
Li M; Kong XY; Wang SM
Cancer Chemother Pharmacol; 2023 Jan; 91(1):77-87. PubMed ID: 36463535
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
Tang SC; Lankheet NA; Poller B; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2012 Apr; 341(1):164-73. PubMed ID: 22238213
[TBL] [Abstract][Full Text] [Related]
18. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
[TBL] [Abstract][Full Text] [Related]
19. The role of the efflux carriers Abcg2 and Abcc2 for the hepatobiliary elimination of benzo[a]pyrene and its metabolites in mice.
Kranz J; Hessel S; Aretz J; Seidel A; Petzinger E; Geyer J; Lampen A
Chem Biol Interact; 2014 Dec; 224():36-41. PubMed ID: 25451572
[TBL] [Abstract][Full Text] [Related]
20. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]